Ontology highlight
ABSTRACT:
SUBMITTER: Addeo A
PROVIDER: S-EPMC6044318 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
Addeo Alfredo A Metro Giulio G
Drugs in context 20180710
In the present editorial we describe the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We focus on the major breakthroughs we have been witnessing in this context, from the introduction of crizotinib as the first approved targeted drug, to the meaningful improvement in terms of clinical benefit that alectinib, a second generation ALK-inhibitor, has recently provided over crizotinib. Finally, we ad ...[more]